ES302
/ Elpiscience
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 27, 2026
ES302, A Novel TL1A/IL-23p19 Bi-specific Antibody Demonstrates Robust Efficacy and Developability for Inflammatory Bowel Disease
(IMMUNOLOGY 2026)
- "ES302 is a highly differentiated antibody with strong potential for the treatment of inflammatory bowel diseases."
Bispecific • Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • IFNG • IL17A • IL23A
1 to 1
Of
1
Go to page
1